Trials / Recruiting
RecruitingNCT05272241
Registry of Asthma Characterization and Recruitment 3 (RACR3)
Registry of Asthma Characterization and Recruitment 3 (RACR3) (CAUSE-02)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Detailed description
Protocol CAUSE-02 RACR3 is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies. Approximately 1,500 participants - of all ages, living in selected Office of Management and Budget (OMB) defined Metropolitan Statistical Areas (MSAs) will be enrolled in the registry. The registry database will be generated with data gathered at a single core visit, followed by optional additional visits. The registry will include assessments of various asthma and allergy characteristics to achieve a more flexible, efficient, selective, and inclusive approach to participant recruitment while still following national guidelines to foster participant safety. CAUSE investigators may invite children or adults without asthma or atopic diseases to participate in the registry as "healthy" controls; for validation of laboratory tests, study monitoring equipment, and/or procedures; or for site procedure training of study personnel for certification and quality assurance. Participants may opt to withdraw their information or discontinue from the registry at any time, in person, by telephone, or in writing.
Conditions
Timeline
- Start date
- 2022-04-15
- Primary completion
- 2028-05-01
- Completion
- 2028-05-01
- First posted
- 2022-03-09
- Last updated
- 2025-06-22
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05272241. Inclusion in this directory is not an endorsement.